Anvisa Approves New Migraine Treatment Medicine
22 Articles
22 Articles
Aquipta Reproduction/AbbVie The National Agency for Health Surveillance (Anvisa) approved the registration of the Aquipta (hydrated atogepant), AbbVie's new oral medicine focused on migraine. The registration expands a recent generation of treatments that act on the CGRP, a molecule that participates in migraine pain mechanisms. Instead of using medicines originally developed for other diseases and then incorporated into crisis prevention, such …
Product acts on pain transmission block and is indicated for adults who have at least four monthly episodes of the disease
Aquipta is indicated for adults who have at least 4 episodes of the disease per month. Read on Power360.
Brasilia, Sept. 8 (Latin Press) Brazil's National Health Surveillance Agency (Anvisa) today approved a new oral medicine to prevent migraine crises in adults with at least four episodes per month. The post They approve in Brazil new anti migraine drug first appeared on News Prensa Latina.
AbbVie's medication is indicated for adults with at least four monthly seizures; it works in blocking the CGRP receptor, a specific pain mechanism, and reduced migraine days in clinical studies. The National Agency for Health Surveillance (Anvisa) approved, on Tuesday (8), the registration of the oral medicine Aquipta (atogepanto), of the pharmacist AbbVie, for prevention [...]
A new medicine for migraine treatment was approved on Tuesday (8) by the National Agency of Health Surveillance (Anvisa). The Aquipta (atogepanto) is indicated for adults who have at least four monthly episodes of migraine. According to the agency, the substance acts in blocking a pathway involved in the transmission of pain. In addition, it is capable of [...] The post Anvisa approves new medicine for migraine treatment in adults appeared first…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
